Metsera/MTSR, and its path to monthly GLP-1 in obesity Metsera (~$2.9bn market cap) is a clinical stage biotech company that has a lead asset MET-097i in Phase 2b for obesity
The long-term prospects of Wegovy -- supplemented by increased manufacturing output and potential new applications -- should not be discounted
This prime supplement, valued by discerning buyers, is ideal for industries seeking advanced performance through high-quality materials
It consists of the tripeptide GHK complexed with a divalent copper ion (Cu 2+ )
Both programs simplify access to GLP-1 treatment, but they differ in how support continues after medication begins
They can address any questions you may have regarding dosing, storage, shipping, or any other matter you need assistance with